Status:
COMPLETED
Pediatric NMOSD Observational Study
Lead Sponsor:
Mayo Clinic
Collaborating Sponsors:
Alexion Pharmaceuticals, Inc.
Conditions:
Neuromyelitis Optica
NMO Spectrum Disorder
Eligibility:
All Genders
2-17 years
Brief Summary
This study is being done to develop a database of pediatric patients in order to study the cause, early detection and best treatment for neuromyelitis optica spectrum disorder (NMOSD) in pediatric pat...
Detailed Description
This study is being done to collect information on the natural history of NMOSD in pediatric AQP4-IgG seropositive patients. A major restriction in performing drug studies in pediatric patients with N...
Eligibility Criteria
Inclusion
- AQP4 positive
- Ability to give informed consent by patient or caregiver
Exclusion
- \- Inability to complete required forms via phone, mail, or email.
Key Trial Info
Start Date :
February 1 2018
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
April 3 2024
Estimated Enrollment :
100 Patients enrolled
Trial Details
Trial ID
NCT03766347
Start Date
February 1 2018
End Date
April 3 2024
Last Update
April 10 2024
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Mayo Clinic
Rochester, Minnesota, United States, 55905